Free Sierra Leone: 2016

Thursday, September 22, 2016

Vosol HC

Vosol HC is a brand name of acetic acid/hydrocortisone otic, approved by the FDA in the following formulation(s):

VOSOL HC (acetic acid, glacial; hydrocortisone - solution/drops; otic)

Manufacturer: HI TECH PHARMA

Approved Prior to Jan 1, 1982

Strength(s): 2%;1% ^[RLD]^[AT]

Has a generic version of Vosol HC been approved?

Yes. The following products are equivalent to Vosol HC:

ACETASOL HC (acetic acid, glacial; hydrocortisone solution/drops; otic)

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: January 13, 1982

Strength(s): 2%;1% ^[AT]

HYDROCORTISONE AND ACETIC ACID (acetic acid, glacial; hydrocortisone solution/drops; otic)

Manufacturer: TARO

Approval date: March 4, 1985

Strength(s): 2%;1% ^[AT]

Manufacturer: VINTAGE

Approval date: February 6, 2006

Strength(s): 2%;1% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vosol HC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Vosol HC.

Has a generic version of Zyloprim been approved?

Yes. The following products are equivalent to Zyloprim:

allopurinol tablet; oral

Manufacturer: APOTEX INC

Approval date: September 8, 2005

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: CARACO

Approval date: August 30, 2007

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: IPCA LABS LTD

Approval date: March 16, 2011

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: January 9, 1987

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: MYLAN

Approval date: October 24, 1986

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: NORTHSTAR HLTHCARE

Approval date: September 11, 2007

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: VINTAGE PHARMS

Approval date: June 27, 2003

Strength(s): 100MG ^[AB], 300MG ^[AB]

Manufacturer: WATSON LABS

Approval date: September 28, 1984

Strength(s): 100MG ^[AB], 300MG ^[AB]

LOPURIN (allopurinol tablet; oral)

Manufacturer: DR REDDYS LA

Approval date: April 2, 1987

Strength(s): 100MG ^[AB], 300MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyloprim. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zyloprim.

Has a generic version of Valturna been approved?

No. There is currently no therapeutically equivalent version of Valturna available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valturna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Acyl compounds
Patent 5,399,578
Issued: March 21, 1995
Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
Assignee(s): Ciba-Geigy Corp
Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
Patent expiration dates:
- March 21, 2012
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug substance
  ✓
  Drug product

.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
Patent 5,559,111
Issued: September 24, 1996
Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
Assignee(s): Ciba-Geigy Corporation
.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
Patent expiration dates:
- July 21, 2018
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- March 5, 2012 - NEW CHEMICAL ENTITY
- September 16, 2012 - NEW COMBINATION

Has a generic version of Zebeta been approved?

Yes. The following products are equivalent to Zebeta:

bisoprolol fumarate tablet; oral

Manufacturer: AUROBINDO PHARMA

Approval date: December 27, 2006

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: MYLAN

Approval date: December 14, 2005

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: SANDOZ

Approval date: November 16, 2000

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: June 26, 2001

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: UNICHEM PHARMS (USA)

Approval date: August 18, 2009

Strength(s): 10MG ^[AB], 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zebeta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zebeta.

Has a generic version of Faslodex been approved?

No. There is currently no therapeutically equivalent version of Faslodex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Faslodex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Formulation
Patent 6,774,122
Issued: August 10, 2004
Inventor(s): John R; Evans & Rosalind U; Grundy
Assignee(s): AstraZeneca AB
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol, more particularly to a formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
Patent expiration dates:
- January 9, 2021
  ✓
  Patent use: TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- July 9, 2021
  ✓
  Pediatric exclusivity

Formulation
Patent 7,456,160
Issued: November 25, 2008
Inventor(s): Evans; John R & Grundy; Rosalind U
Assignee(s): AstraZeneca AB
The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
Patent expiration dates:
- January 9, 2021
  ✓
  Patent use: TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- July 9, 2021
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- September 9, 2013 - CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
- March 9, 2014 - PEDIATRIC EXCLUSIVITY
- May 17, 2014 - SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
- November 17, 2014 - PEDIATRIC EXCLUSIVITY

Has a generic version of Zomig-ZMT been approved?

No. There is currently no therapeutically equivalent version of Zomig-ZMT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig-ZMT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Indolyl compounds for treating migraine
Patent 5,466,699
Issued: November 14, 1995
Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
Assignee(s): Burroughs Wellcome Co.
##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
Patent expiration dates:
- November 14, 2012
- May 14, 2013
  ✓
  Pediatric exclusivity

Has a generic version of Zolpimist been approved?

No. There is currently no therapeutically equivalent version of Zolpimist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zolpimist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Buccal, polar and non-polar spray containing zolpidem
Patent 7,632,517
Issued: December 15, 2009
Inventor(s): Dugger, III; Harry A. & Abd El-Shafy; Mohammed
Assignee(s): Novadel Pharma Inc.
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.
Patent expiration dates:
- October 1, 2017
  ✓
  Patent use: TREATMENT OF TRANSIENT INSOMNIA

Has a generic version of FML been approved?

No. There is currently no therapeutically equivalent version of FML available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of FML. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with FML.

Has a generic version of Furadantin been approved?

Yes. The following products are equivalent to Furadantin:

nitrofurantoin suspension; oral

Manufacturer: AMNEAL PHARMS

Approval date: May 11, 2011

Strength(s): 25MG/5ML ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Furadantin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Furadantin.

Has a generic version of Visicol been approved?

No. There is currently no therapeutically equivalent version of Visicol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Visicol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Non-aqueous colonic purgative formulations
Patent 5,616,346
Issued: April 1, 1997
Inventor(s): Aronchick; Craig A.
Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of monobasic, dibasic and tribasic sodium phosphates administered in tablet or capsule form in concentrations of from 0.01 to 0.85 grams per kilogram body weight. Preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.
Patent expiration dates:
- May 18, 2013
  ✓
  Patent use: METHOD OF USE OF VISICOL

Has a generic version of Zelapar been approved?

No. There is currently no therapeutically equivalent version of Zelapar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zelapar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical and other dosage forms
Patent 5,648,093
Issued: July 15, 1997
Inventor(s): Gole; Dilip J. & Levinson; R. Saul & Wilkinson; Paul K. & Davies; J. Desmond
Assignee(s): Janssen Pharmaceutica Inc.
A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms is disclosed.
Patent expiration dates:
- July 15, 2014
  ✓
  Drug product

Process for the preparation of a solid pharmaceutical dosage form
Patent 6,423,342
Issued: July 23, 2002
Inventor(s): Andrew William; Jordan & Joy Elaine; Saunders & Patrick; Kearney
Assignee(s): R. P. Scherer Corporation
A process for the preparation of a solid pharmaceutical dosage form comprising a carrier and, as active ingredient, a compound which exists, in solution, in an equilibrium between a free acid or free base form and a salt form, and for which there is a difference in volatility between the free acid or free base form and the salt form. The process includes the steps of solidifying a mixture of the compound and carrier in a solvent, and subsequently removing the solvent from the solidified mixture. A pH modifier is added to the mixture prior to solidification to shift the equilibrium to favor the less volatile form of the active ingredient.
Patent expiration dates:
- March 1, 2016
  ✓
  Drug product

Has a generic version of Zetia been approved?

No. There is currently no therapeutically equivalent version of Zetia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zetia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Patent 5,846,966
Issued: December 8, 1998
Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
Assignee(s): Schering Corporation
Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4 -substituted aryl; Ar.sup.3 is aryl or R.sup.5 -substituted aryl; X, Y and Z are --CH.sub.2 --, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6 R.sup.7 ; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sup.5, --CF.sub.3, --CN, --NO.sub.2 and halogen; R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5 OR.sup.6, --O(CO)NR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.6 (CO)R.sup.7, --NR.sup.6 (CO)OR.sup.9, --NR.sup.6 (CO)NR.sup.7 R.sup.8, --NR.sup.6 SO.sub.2 R.sup.9, --COOR.sup.6, --CONR.sup.6 R.sup.7, --COR.sup.6, --SO.sub.2 NR.sup.6 R.sup.7, S(O).sub.0-2 R.sup.9, --O(CH.sub.2).sub.1-10 --COOR.sup.6, --O(CH.sub.2).sub.1-10 CONR.sup.6 R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6 ; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl, aryl or aryl-substituted lower alkyl; R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them, and a process for preparing them.
Patent expiration dates:
- September 21, 2013
  ✓
  Patent use: TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- September 21, 2013
  ✓
  Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- September 21, 2013
  ✓
  Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- March 21, 2014
  ✓
  Pediatric exclusivity

Sterol absorption inhibitor compositions
Patent 7,030,106
Issued: April 18, 2006
Inventor(s): Cho; Wing-Kee Philip
Assignee(s): Schering Corporation
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Patent expiration dates:
- January 25, 2022
  ✓
  Drug product
- July 25, 2022
  ✓
  Pediatric exclusivity

Methods for inhibiting sterol absorption
Patent 7,612,058
Issued: November 3, 2009
Inventor(s): Cho; Wing-Kee Philip
Assignee(s): Schering Corporation
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Patent expiration dates:
- January 25, 2022
  ✓
  Patent use: REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
- January 25, 2022
  ✓
  Patent use: TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- July 25, 2022
  ✓
  Pediatric exclusivity

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Patent RE37721
Issued: May 28, 2002
Inventor(s): Stuart B.; Rosenblum & Sundeep; Dugar & Duane A.; Burnett & John W.; Clader & Brian A.; McKittrick
Assignee(s): Schering Corporation
Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH&boxH;CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
Patent expiration dates:
- October 25, 2016
  ✓
  Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
  ✓
  Drug substance
  ✓
  Drug product
- April 25, 2017
  ✓
  Pediatric exclusivity

Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Patent RE42461
Issued: June 14, 2011
Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
Assignee(s): Schering Corporation
Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
Patent expiration dates:
- October 25, 2016
  ✓
  Patent use: TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
  ✓
  Drug substance
  ✓
  Drug product
- October 25, 2016
  ✓
  Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
  ✓
  Drug substance
  ✓
  Drug product
- April 25, 2017
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- June 5, 2011 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- December 5, 2011 - PEDIATRIC EXCLUSIVITY
- January 24, 2015 - CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL

Has a generic version of Flagyl been approved?

Yes. The following products are equivalent to Flagyl:

metronidazole capsule; oral

Manufacturer: ALEMBIC LTD

Approval date: June 23, 2009

Strength(s): 375MG ^[AB]

Manufacturer: PAR PHARM

Approval date: January 29, 2004

Strength(s): 375MG ^[AB]

metronidazole tablet; oral

Manufacturer: ALEMBIC PHARMS LTD

Approval date: March 13, 2009

Strength(s): 250MG ^[AB], 500MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: July 16, 1986

Strength(s): 250MG ^[AB], 500MG ^[AB]

Manufacturer: PLIVA

Approval date: November 6, 1984

Strength(s): 250MG ^[AB]

Manufacturer: PLIVA

Approval date: December 6, 1984

Strength(s): 500MG ^[AB]

Manufacturer: TEVA

Approval date: February 8, 1985

Strength(s): 500MG ^[AB]

Manufacturer: WATSON LABS

Approval date: September 17, 1982

Strength(s): 250MG ^[AB]

Manufacturer: WATSON LABS

Approval date: December 20, 1982

Strength(s): 500MG ^[AB]

Manufacturer: WATSON LABS

Approval date: December 20, 1984

Strength(s): 250MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flagyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Flagyl.

Has a generic version of Zovirax Ointment been approved?

No. There is currently no therapeutically equivalent version of Zovirax Ointment available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zovirax Ointment. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zovirax Ointment.

Has a generic version of Zyprexa been approved?

A generic version of Zyprexa has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zyprexa and have been approved by the FDA:

olanzapine injectable; intramuscular

Manufacturer: INNOPHARMA LLC

Approval date: October 24, 2011

Strength(s): 10MG/VIAL ^[AP]

olanzapine tablet; oral

Manufacturer: DR REDDYS LABS LTD

Approval date: October 24, 2011

Strength(s): 20MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: October 24, 2011

Strength(s): 10MG ^[AB], 15MG ^[AB], 2.5MG ^[AB], 5MG ^[AB], 7.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyprexa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

2-methyl-thieno-benzodiazepine
Patent 5,229,382
Issued: July 20, 1993
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

2-methyl-thieno-benzodiazepine
Patent 5,605,897
Issued: February 25, 1997
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Eli Lilly and Company
Lilly Industries Limited
Olanzapine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- February 25, 2014
  ✓
  Patent use: METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
- August 25, 2014
  ✓
  Pediatric exclusivity

2-methyl-thieno-benzodiazepine
Patent 5,627,178
Issued: May 6, 1997
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Olanzapine polymorph crystal form
Patent 5,736,541
Issued: April 7, 1998
Inventor(s): Bunnell; Charles Arthur & Hendriksen; Barry Arnold & Larsen; Samuel Dean
Assignee(s): Eli Lilly and Company
Eli Lilly and Company
The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.
Patent expiration dates:
- March 24, 2015
  ✓
  Patent use: CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
- September 24, 2015
  ✓
  Pediatric exclusivity

Methods of treatment using a thieno-benzodiazepine
Patent 5,817,655
Issued: October 6, 1998
Inventor(s): Chakrabarti; Jiban Kumar & Hotten; Terrence Micharl & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno -›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Mental disorders
Patent 5,817,656
Issued: October 6, 1998
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban Kumar & Hotten; Terrence Michael & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Psychoactive substance disorders
Patent 5,817,657
Issued: October 6, 1998
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban Kumar & Hotten; Terrence Michael & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Oral 2-methyl-thieno-benzodiazepine formulation
Patent 5,919,485
Issued: July 6, 1999
Inventor(s): Cochran; George Randall & Morris; Tommy Clifford
Assignee(s): Eli Lilly and Company
The invention provides a pharmaceutically acceptable solid oral formulation of olanzapine and a process for making such formulation.
Patent expiration dates:
- March 24, 2015
  ✓
  Patent use: CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
- September 24, 2015
  ✓
  Pediatric exclusivity

Olanzapine dihydrate D
Patent 6,251,895
Issued: June 26, 2001
Inventor(s): Larsen; Samuel Dean & Nichols; John Richard & Reutzel; Susan Marie & Stephenson; Gregory Alan
Assignee(s): Eli Lilly and Company
The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.
Patent expiration dates:
- September 23, 2017
- March 23, 2018
  ✓
  Pediatric exclusivity

Combination therapy for treatment of refractory depression
Patent 6,960,577
Issued: November 1, 2005
Inventor(s): Tollefson; Gary Dennis
Assignee(s): Eli Lilly and Company
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
Patent expiration dates:
- November 1, 2017
  ✓
  Patent use: PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

Related Exclusivities

Exclusivity expiration dates:
- March 19, 2012 - TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- December 4, 2012 - NEW PATIENT POPULATION
- June 4, 2013 - PEDIATRIC EXCLUSIVITY

Has a generic version of Zinecard been approved?

Yes. The following products are equivalent to Zinecard:

dexrazoxane hydrochloride injectable; injection

Manufacturer: BEDFORD

Approval date: September 28, 2004

Strength(s): EQ 250MG BASE/VIAL ^[AP], EQ 500MG BASE/VIAL ^[AP]

Manufacturer: MYLAN INSTITUTIONAL

Approval date: October 19, 2011

Strength(s): EQ 250MG BASE/VIAL ^[AP], EQ 500MG BASE/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zinecard. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zinecard.

Wednesday, September 21, 2016

Focalin XR

FOCALIN XR (dexmethylphenidate hydrochloride - capsule, extended release; oral)

Manufacturer: NOVARTIS

Approval date: May 26, 2005

Strength(s): 10MG, 20MG, 5MG

Manufacturer: NOVARTIS

Approval date: August 1, 2006

Strength(s): 15MG

Manufacturer: NOVARTIS

Approval date: October 23, 2009

Strength(s): 30MG

Manufacturer: NOVARTIS

Approval date: August 11, 2010

Strength(s): 40MG ^[RLD]

Manufacturer: NOVARTIS

Approval date: April 21, 2011

Strength(s): 25MG, 35MG

Has a generic version of Focalin XR been approved?

No. There is currently no therapeutically equivalent version of Focalin XR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Focalin XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Delivery of multiple doses of medications
Patent 5,837,284
Issued: November 17, 1998
Inventor(s): Mehta; Atul M. & Zeitlin; Andrew L. & Dariani; Maghsoud M.
Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
Patent expiration dates:
- December 4, 2015
  ✓
  Drug product
- December 4, 2015
  ✓
  Patent use: A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
  ✓
  Drug product

Method of treating attention deficit disorders with d-threo methylphenidate
Patent 5,908,850
Issued: June 1, 1999
Inventor(s): Zeitlin; Andrew L. & Dariani; Maghsoud M. & Stirling; David I.
Assignee(s): Celgene Corporation
Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.
Patent expiration dates:
- December 4, 2015
  ✓
  Patent use: METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
- December 4, 2015
  ✓
  Patent use: METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
  ✓
  Drug product

Multiparticulate modified release composition
Patent 6,228,398
Issued: May 8, 2001
Inventor(s): Devane; John G. & Stark; Paul & Fanning; Niall M. M.
Assignee(s): Elan Corporation, PLC
The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component compnsimg a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.
Patent expiration dates:
- November 1, 2019
  ✓
  Patent use: METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
  ✓
  Drug product

Phenidate drug formulations having diminished abuse potential
Patent 6,355,656
Issued: March 12, 2002
Inventor(s): Andrew L.; Zeitlin & Maghsoud M.; Dariani
Assignee(s): Celgene Corporation
Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Patent expiration dates:
- December 4, 2015
  ✓
  Drug product

Phenidate drug formulations having diminished abuse potential
Patent 6,528,530
Issued: March 4, 2003
Inventor(s): Andrew L.; Zeitlin & Maghsoud M.; Dariani
Assignee(s): Celgene Corporation
Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Patent expiration dates:
- December 4, 2015
  ✓
  Drug product

Delivery of multiple doses of medications
Patent 6,635,284
Issued: October 21, 2003
Inventor(s): Atul M.; Mehta & Andrew L.; Zeitlin & Maghsoud M.; Dariani
Assignee(s): Celegene Corporation
Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
Patent expiration dates:
- December 4, 2015
  ✓
  Patent use: A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
  ✓
  Drug product

Multiparticulate modified release composition
Patent 6,730,325
Issued: May 4, 2004
Inventor(s): John G.; Devane & Paul; Stark & Niall M. M.; Fanning
Assignee(s): Elan Corporation, plc
The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.
Patent expiration dates:
- November 1, 2019
  ✓
  Patent use: METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
  ✓
  Drug product

Delivery of multiple doses of medications
Patent 7,431,944
Issued: October 7, 2008
Inventor(s): Mehta; Atul M. & Zeitlin; Andrew L. & Dariani; Maghsoud M.
Assignee(s): Celgene Corporation
Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
Patent expiration dates:
- December 4, 2015
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- October 17, 2011 - ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- October 23, 2012 - CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

Has a generic version of Zometa been approved?

No. There is currently no therapeutically equivalent version of Zometa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zometa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted alkanediphosphonic acids and pharmaceutical use
Patent 4,939,130
Issued: July 3, 1990
Inventor(s): Jaeggi; Knut A. & Widler; Leo
Assignee(s): Ciba-Geigy Corporation
Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
Patent expiration dates:
- September 2, 2012
  ✓
  Patent use: HYPERCALCEMIA OF MALIGNANCY
  ✓
  Drug substance
  ✓
  Drug product
- March 2, 2013
  ✓
  Pediatric exclusivity

Pharmaceutical products comprising bisphosphonates
Patent 7,932,241
Issued: April 26, 2011
Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
Assignee(s): Novartis AG
A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Patent expiration dates:
- February 5, 2028
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- March 20, 2011 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- September 20, 2011 - PEDIATRIC EXCLUSIVITY

Has a generic version of Fanapt been approved?

No. There is currently no therapeutically equivalent version of Fanapt available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fanapt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
Patent RE39198
Issued: July 18, 2006
Inventor(s): Strupczewski; Joseph T. & Helsley; Grover C. & Chiang; Yulin & Bordeau; Kenneth J. & Glamkowski; Edward J.
Assignee(s): Aventis Pharmaceuticals Inc.
Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Patent expiration dates:
- November 15, 2016
  ✓
  Patent use: INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- May 6, 2014 - NEW CHEMICAL ENTITY

Has a generic version of Zestoretic been approved?

Yes. The following products are equivalent to Zestoretic:

LISINOPRIL AND HYDROCHLOROTHIAZIDE (hydrochlorothiazide; lisinopril tablet; oral)

Manufacturer: APOTEX INC

Approval date: October 5, 2004

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: AUROBINDO

Approval date: March 14, 2006

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: LUPIN

Approval date: September 27, 2006

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: MYLAN

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: PRINSTON INC

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: RANBAXY

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: SANDOZ

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: WATSON LABS

Approval date: July 1, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

Manufacturer: WEST WARD

Approval date: July 8, 2002

Strength(s): 12.5MG;10MG ^[AB], 12.5MG;20MG ^[AB], 25MG;20MG ^[AB]

PRINZIDE (hydrochlorothiazide; lisinopril tablet; oral)

Manufacturer: MERCK

Approval date: February 16, 1989

Strength(s): 12.5MG;20MG ^[AB]

Manufacturer: MERCK

Approval date: November 18, 1993

Strength(s): 12.5MG;10MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zestoretic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zestoretic.

Thursday, September 22, 2016

VOSOL HC (acetic acid, glacial; hydrocortisone - solution/drops; otic)

Has a generic version of Vosol HC been approved?

ACETASOL HC (acetic acid, glacial; hydrocortisone solution/drops; otic)

HYDROCORTISONE AND ACETIC ACID (acetic acid, glacial; hydrocortisone solution/drops; otic)

Related Patents

See also...

ZYLOPRIM (allopurinol - tablet; oral)

Has a generic version of Zyloprim been approved?

allopurinol tablet; oral

LOPURIN (allopurinol tablet; oral)

Related Patents

See also...

VALTURNA (aliskiren hemifumarate; valsartan - tablet; oral)

Has a generic version of Valturna been approved?

Related Patents

Related Exclusivities

See also...

ZEBETA (bisoprolol fumarate - tablet; oral)

Has a generic version of Zebeta been approved?

bisoprolol fumarate tablet; oral

Related Patents

See also...

FASLODEX (fulvestrant - injectable; intramuscular)

Has a generic version of Faslodex been approved?

Related Patents

Related Exclusivities

See also...

ZOMIG-ZMT (zolmitriptan - tablet, orally disintegrating; oral)

Has a generic version of Zomig-ZMT been approved?

Related Patents

See also...

ZOLPIMIST (zolpidem tartrate - spray, metered; oral)

Has a generic version of Zolpimist been approved?

Related Patents

See also...

FML (fluorometholone - ointment; ophthalmic)

FML (fluorometholone - suspension/drops; ophthalmic)

Has a generic version of FML been approved?

Related Patents

See also...

FURADANTIN (nitrofurantoin - suspension; oral)

Has a generic version of Furadantin been approved?

nitrofurantoin suspension; oral

Related Patents

See also...

VISICOL (sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate - tablet; oral)

Has a generic version of Visicol been approved?

Related Patents

See also...

ZELAPAR (selegiline hydrochloride - tablet, orally disintegrating; oral)

Has a generic version of Zelapar been approved?

Related Patents

See also...

ZETIA (ezetimibe - tablet; oral)

Has a generic version of Zetia been approved?

Related Patents

Related Exclusivities

See also...

FLAGYL (metronidazole - capsule; oral)

FLAGYL (metronidazole - tablet; oral)

Has a generic version of Flagyl been approved?

metronidazole capsule; oral

metronidazole tablet; oral

Related Patents

See also...

ZOVIRAX (acyclovir - cream; topical)

ZOVIRAX (acyclovir - ointment; topical)

Has a generic version of Zovirax Ointment been approved?

Related Patents

See also...

ZYPREXA (olanzapine - injectable; intramuscular)

ZYPREXA (olanzapine - tablet; oral)

Has a generic version of Zyprexa been approved?

olanzapine injectable; intramuscular

olanzapine tablet; oral

Related Patents

Related Exclusivities

See also...

ZINECARD (dexrazoxane hydrochloride - injectable; injection)